首页> 美国卫生研究院文献>Molecular Therapy >Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response
【2h】

Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response

机译:体内树突状细胞靶向脂质体DNA疫苗载体的遗传免疫诱导持久的抗肿瘤免疫反应。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A major limiting factor retarding the clinical success of dendritic cell (DC)-based genetic immunizations (DNA vaccination) is the scarcity of biologically safe and effective carrier systems for targeting the antigen-encoded DNA vaccines to DCs under in vivo settings. Herein, we report on a potent, mannose receptor selective in vivo DC-targeting liposomes of a novel cationic amphiphile with mannose-mimicking shikimoyl head-group. Flow cytometric experiments with cells isolated from draining lymph nodes of mice s.c. immunized with lipoplexes of pGFP plasmid (model DNA vaccine) using anti-CD11c antibody-labeled magnetic beads revealed in vivo DC-targeting properties of the presently described liposomal DNA vaccine carrier. Importantly, s.c. immunizations of mice with electrostatic complex of the in vivo DC-targeting liposome and melanoma antigen-encoded DNA vaccine (p-CMV-MART1) induced long-lasting antimelanoma immune response (100 days post melanoma tumor challenge) with remarkable memory response (more than 6 months after the second tumor challenge). The presently described direct in vivo DC-targeting liposomal DNA vaccine carrier is expected to find future exploitations toward designing effective vaccines for various infectious diseases and cancers.
机译:阻碍基于树突细胞(DC)的基因免疫(DNA疫苗接种)的临床成功的主要限制因素是缺乏在体内环境下将抗原编码的DNA疫苗靶向DC的生物学安全有效的载体系统。在本文中,我们报道了一种新型的阳离子两亲物,具有模仿甘露糖的sh草酰基头基团的强效,甘露糖受体选择性体内靶向DC的脂质体。流式细胞仪实验,细胞分离自小鼠排水管的淋巴结。用抗CD11c抗体标记的磁珠用pGFP质粒的脂质复合物(模型DNA疫苗)免疫,揭示了本文所述脂质体DNA疫苗载体的体内DC靶向特性。重要的是用体内靶向DC的脂质体和黑色素瘤抗原编码的DNA疫苗(p-CMV-MART1)的静电复合物对小鼠进行免疫,可诱导持久的an虫免疫应答(黑色素瘤激发后100天),并具有显着的记忆应答(超过第二次肿瘤攻击后6个月)。目前描述的直接体内靶向DC的脂质体DNA疫苗载体有望在设计针对各种传染性疾病和癌症的有效疫苗方面找到未来的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号